Biweekly peglated liposomal doxorubicin/oxaliplatin for ovarian cancer resistant to taxane-platinum treatment: A Phase II study.
Indian J Cancer
;
2012 Jan-Mar; 49(1): 169-175
Article
in English
| IMSEAR
| ID: sea-144567
ABSTRACT
Aim:
The aim of this Phase II study was to evaluate the activity and safety of biweekly pegylated liposomal doxorubicin (PLD) and oxaliplatin (L-OHP) in patients with platinum-taxane resistant ovarian cancer. Materials andMethods:
Treatment consisted of PLD (20 mg/m 2 ) on Day 1; and L-OHP (50 mg/m 2 ) administered on Days 1 and 2, every two weeks. Response to therapy was assessed using the Response Evaluation Criteria in Solid Tumors RECIST ; toxicity was evaluated by the National Cancer Institute Common Toxicity Criteria.Results:
Forty patients pretreated with platinum/taxane chemotherapy, with a median age of 61 years, were recruited for the study. Thirty-eight patients were available for response evaluation three complete responses and nine partial responses were registered; resulting in an overall response rate of 31.5%. Twenty-eight patients gained clinical benefit (73.7%) from this chemotherapy regimen. Median time to progression (TTP) and overall survival (OS) were 5.5 and 10 months respectively. The hematological and non-hematological toxicity profile was favorable. No Grade 4 toxicity was observed. Major toxicities included Grade 3 neutropenia (13.2%), Grade 2 palmar-plantar erythrodysesthesia (7.9%), and Grade 1-2 neuropathy in 15.8% of patients.Conclusion:
Biweekly PLD and L-OHP combination has high activity, with less than anticipated adverse toxicity, for treatment of platinum-resistant ovarian cancer. A comparison of the doublet PLD/L-OHP with single-agent treatment is warranted.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Organoplatinum Compounds
/
Ovarian Neoplasms
/
Bridged-Ring Compounds
/
Aged
/
Female
/
Humans
/
Antineoplastic Combined Chemotherapy Protocols
/
Doxorubicin
/
Survival Analysis
/
Drug Resistance, Neoplasm
Language:
English
Journal:
Indian J Cancer
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS